**Analysis:** IBIO's recent plunge (close: $1.51 on Apr 7) screams bearish 📉, with the 9-day EMA ($3.49) crossing below the 21-day ($4.07)—a classic downtrend signal. RSI at 26.9 hints at oversold conditions, but the massive volume spike (3.2M vs. avg ~500K) suggests panic selling, not accumulation. News shows volatility (triples then drops 41% 🎢) amid drug pipeline hype. No clear reversal pattern yet—avoid catching the falling knife. Wait for RSI rebound + volume confirmation before considering a dip-buy. Hold/sell for now. 🚦

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

iBio, Inc. IBIO: 0.8899 USD

Bearish views